Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,848
  • Shares Outstanding, K 6,862
  • Annual Sales, $ 5,210 K
  • Annual Income, $ -22,390 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.03
  • Price/Sales 7.83
  • Price/Cash Flow N/A
  • Price/Book 8.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.94
  • Number of Estimates 2
  • High Estimate $-0.89
  • Low Estimate $-1.00
  • Prior Year $-14.00
  • Growth Rate Est. (year over year) +93.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.90 +151.72%
on 04/07/26
7.41 -1.42%
on 04/20/26
+1.10 (+17.79%)
since 03/20/26
3-Month
2.90 +151.72%
on 04/07/26
8.73 -16.33%
on 02/25/26
+0.17 (+2.38%)
since 01/20/26
52-Week
2.90 +151.72%
on 04/07/26
30.50 -76.07%
on 04/23/25
-9.16 (-55.66%)
since 04/17/25

Most Recent Stories

More News
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 7.30 (+14.24%)
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 7.30 (+14.24%)
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

HOUSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...

PSTV : 7.30 (+14.24%)
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 7.30 (+14.24%)
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (“Plus” or the “Company”), today announces a new...

PSTV : 7.30 (+14.24%)
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 7.30 (+14.24%)
Plus Therapeutics Announces Reverse Stock Split 

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies...

PSTV : 7.30 (+14.24%)
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 7.30 (+14.24%)
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 7.30 (+14.24%)
Plus: Q4 Earnings Snapshot

Plus: Q4 Earnings Snapshot

PSTV : 7.30 (+14.24%)

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 8.73
2nd Resistance Point 8.07
1st Resistance Point 7.68
Last Price 7.30
1st Support Level 6.64
2nd Support Level 5.98
3rd Support Level 5.59

See More

52-Week High 30.50
Fibonacci 61.8% 19.96
Fibonacci 50% 16.70
Fibonacci 38.2% 13.44
Last Price 7.30
52-Week Low 2.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.